The Rapid Capture System is a semi-automated pipetting and microplate handling system for high-volume sample-throughput testing. This system handles up to 352 specimens and 1 to 4 plates in a single 8 hour shift. The Rapid Capture System fits on a standard bench top and is compatible with software that provides LIS interface connectivity.
The Rapid Capture System (RCS) is FDA-approved (see IVD mark) for use with the digene HC2 High-Risk HPV DNA Test, digene HC2 CT/GC DNA Test, digene HC2 CT-ID DNA Test, and the digene HC2 GC-ID DNA Test. The system processes cervical samples collected in Specimen Transport Medium (STM), which is part of the digene Cervical Sampler. Other digene tests or sample types may be available for use on the RCS, depending on country regulations. Onboard reagent stability The RCS provides reagent stability of 16 hours for those reagents most likely to be subject to extended onboard placement — Probe Mix, Detection Reagent 1, Detection Reagent 2, and the Capture Plates (see table). Agreement of calibrator and control results of fresh vs. aged reagents Overall agreement Positive agreement Negative agreement R 2 Slope Intercept Kappa 100% 96/97 (97.97–100) 100% 64/64 (97.97–100) 100% 32/32 (97.97–100) 0.9936 0.97 0.47 1.0 The assay performance of reagents was evaluated using freshly prepared reagents vs. reagents that were aged onboard the Rapid Capture System platform at room temperature for a period of 16 hours to simulate 2 work shifts in a laboratory setting. Simulated clinical specimens were tested using 2 Rapid Capture Systems each on 2 days (RCS 1: aged reagents on day 1 and fresh reagents on day 2; RCS 2: fresh reagents on day 1 and aged reagents on day 2). Results were comparable for fresh vs. aged reagents (CI: 95%), indicating that reagents are sufficiently stable when placed onboard the instrument for a period of up to 16 hours. Agreement of Rapid Capture System vs. manual HPV test methods The Rapid Capture System HPV application results show agreement with the manual method in clinical specimens. Statistical agreement was shown for cervical specimens collected in ThinPrep PreservCyt solution and STM (see tables). RCS vs. manual HPV test method: STM patient specimen data (n=1001) Cyt. class. HPV preval. % Overall + agreement % (n/N) Strong + region (>2.5) Overall – agreement % (n/N) Strong – region (<0.8) WNL <30 years 21% 99.3% (139/140) 96.1, 100 99.1% (112/113) 95.2, 100 99.3% (538/542) 98.1, 99.8 100% (531/531) 99.3, 100 WNL 30+ years 15% 92.0% (23/25)96.1, 100 93.8% (15/16)69.8, 99.8 100% (143/143) 97.5, 100 100% (142/142) 97.4, 100 ASC-US 65% 98.1% (51/52)89.7, 100 100% (47/47)92.4, 100 96.4% (27/28) 81.7, 99.9 100% (26/26) 86.8, 100 LSIL+ 96% 100% (65/65) 94.5, 100 100%(62/62) 94.2, 100 66.7% (2/3) 9.4, 99.2 66.7% (2/3) 9.4, 99.2 Other 33% 100% (1/1) 2.5, 100 100% (1/1) 2.5, 100 100% (2/2) 15.8, 100 100% (2/2) 15.8, 100 All STM 28% 98.6% (279/283) 96.4, 99.6 99.2% (237/239) 97.0, 99.9 99.2% (712/718) 98.2, 99.7 99.9% (703/704) 99.2, 100 Clinical results using the Rapid Capture System were compared with results obtained using the manual method in a multicenter study (N=2270 patients). Patient specimens were collected from 5 collection sites and testing was performed at 3 external sites. The data set consisted of cervical specimens collected in ThinPrep PreservCyt Solution (1269) and Specimen Transport Medium (1001). Confidence interval=95%. LSIL+: low-grade squamous intraepithelial lesion or greater; +: positive; –: negative; ASC-US: atypical squamous cells of undetermined significance; STM: Specimen Transport Medium; WNL: within normal limits. RCS vs. manual HPV test method ThinPrep PreservCyt clinical specimen data (n=1269) Cyt. class HPV preval. % Overall + agreement % (n/N) Strong + region (>2.5) Overall agreement % (n/N) Strong – region (<0.8) WNL <30 years 20% 96.2% (75/78) 89.2, 99.2 100% (64/64) 94.4, 100 98.4% (301/306) 96.2, 99.5 99.0% (293/296) 97.1, 99.8 WNL 30+ years 8% 88.7 (47/53) 77.0, 95.7 92.1% (35/38) 78.6, 98.3 99.1% (578/583) 98.0, 99.7 99.5% (571/574) 98.5, 99.9 ASC-US 36% 100% (48/48) 92.6, 100 100% (46/46) 92.3, 100 96.6% (84/87) 90.3, 99.3 96.5% (83/86) 90.1, 99.3 LSIL+ 77% 100% (64/64) 94.4, 100 100% (62/62) 94.2, 100 89.5% (17/19) 66.9, 98.7 88.9% (16/18) 65.3, 98.6 Other 11% 100% (3/3) 29.2, 100 100% (3/3) 29.2, 100 100% (24/24) 85.6, 100 100% (24/24) 85.8, 100 All PreservCyt Clinical 20% 96.4% (238/247) 93.2, 98.3 98.6% (211/214) 96.0, 99.7 98.5% (1007/1022) 97.6, 99.2 98.9% (990/1001) 98.0, 99.4 Clinical results using the Rapid Capture System were compared with those obtained with the manual method in a multicenter study (N=2270 patients). Patient specimens were collected from 5 collection sites, with testing performed at 3 external sites. The data set consisted of cervical specimens collected in ThinPrep PreservCyt Solution (1269) and Specimen Transport Medium (1001). In the results for the ThinPrep PreservCyt Solution, cytology data was unavailable from 4 patients. Confidence interval = 95%. LSIL+: low-grade squamous intraepithelial lesion or greater; +: positive; –: negative; ASC-US: atypical squamous cells of undetermined significance; WNL: within normal limits.
The Rapid Capture System reduces repetitive manual steps, with technology that performs semi-automated assays. The system is designed to work with the Hybrid Capture 2 screening technology, and it is the only high-throughput system for testing cervical samples with the FDA-approved digene HC2 High-Risk HPV DNA Test. The Rapid Capture system provides the flexibility of multiple software scripts, allowing laboratories to adjust their schedules to improve workflow. Specimen contamination or carryover of residual alkaline phophotase is minimized through the use of disposable pipette tips for reagent and specimen aspiration. The system automates sample transfers (from sample tubes to hybridization plate, then from hybridization plate to Capture Plate), plate handline, precision reagent pipetting with liquid level-sensing tips, incubation at ambient and 65°C temperatures, and washing.
Multiple assays for flexible workflows The Rapid Capture System (RCS) accommodates multiple assays or sample types during a single run — enabling scheduling flexibility. For instance, when running a single run of the digene HC2 High-Risk HPV DNA Test on the RCS, separate plates can handle both liquid based cytology (LBC) samples and digene cervical samples. The Rapid Capture System can be used with the digene HC2 High-Risk HPV DNA Test, digene HC2 CT-ID DNA test, and digene HC2 GC-ID DNA Test. Depending on the test, the specimens can be collected using the digene Cervical Sampler, Specimen Transport Medium (STM), digene Female Swab Specimen Collection Kit, and PreservCyt solution. High-throughput design for optimized workflow The Rapid Capture System performs up to 352 tests/8 hours, automating 6 procedural steps of the manual method: Specimen pipetting Regent dispensing Microplate handling Microplate mixing Microplate incubation Microplate washing User intervention is limited to specimen preparation, loading of specimen racks onto the deck, deck setup, chemiluminescent signal detection, and result reporting. Denaturation of the specimens in preparation for testing with the digene HC2 DNA Tests is performed independently of the Rapid Capture System. In addition, amplified chemiluminescent signal detection and result reporting are performed using the offline DML 2000/3000 Instrument and using the digene Hybrid Capture System Version 2 (DHCS v.2) Software. The Rapid Capture System is intended to be used only in combination with QIAGEN kits indicated for use with the Rapid Capture System for applications described in the kit handbooks.
